Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Treatment accessibility sits at the center of this dementia and brain health question.
Treatment accessibility programs are working to ensure that newly approved Alzheimer’s drugs reach patients who need them, though significant barriers remain. Lecanemab, the first disease-modifying Alzheimer’s medication to show meaningful clinical benefit, has undergone a dramatic shift in how it is delivered since FDA approval in 2023. In January 2025, the FDA approved a maintenance schedule allowing patients to receive IV Leqembi injections every 4 weeks after initial biweekly dosing, reducing the frequency of clinic visits. More significantly, in August 2025, the FDA approved LEQEMBI IQLIK, a once-weekly subcutaneous injection that patients can administer at home, fundamentally changing what “accessibility” means for this treatment. These formulation advances represent the core work of accessibility programs: removing the logistical obstacles that prevent people from receiving treatment.
Yet approval and availability are not the same thing. The current standard Alzheimer’s therapies still require intensive intravenous infusions every 2 to 4 weeks paired with rigorous MRI monitoring to watch for a rare but serious side effect called amyloid-related imaging abnormalities (ARIA). Healthcare systems in rural areas, understaffed clinics, and regions without specialized infusion centers struggle to accommodate these demands. Treatment accessibility programs operate at multiple levels—from insurance companies negotiating coverage to patient advocacy organizations providing navigation support to researchers developing easier-to-administer pill formulations. Understanding how these programs work, and where they fall short, matters because it determines whether a breakthrough drug remains inaccessible to the people it was designed to help.
Table of Contents
- What Do Accessibility Programs Actually Do?
- The Challenge of Getting Approved Drugs to Patients
- How New Drug Formulations Are Improving Access
- Insurance Coverage and Practical Access to Lecanemab
- The Biomarker Testing Barrier and Its Impact
- Support Services and Patient Navigation
- The Future of Alzheimer’s Treatment Access
- Conclusion
What Do Accessibility Programs Actually Do?
Alzheimer’s treatment accessibility programs function as bridges between regulatory approval and patient access. These programs include Medicare coverage pathways, patient assistance services, insurance company initiatives, and educational campaigns led by organizations like the Alzheimer’s Association. The Alzheimer’s Association operates a 24-hour Call Center at 1-800-272-3900 serving people across 56 states and territories with free information, care consultation, and local referrals. When a patient calls, they might receive help understanding whether they are eligible for lecanemab treatment, learn where nearby clinics can administer the drug, discover financial assistance programs, or locate support groups for their family. These services address the reality that an approved drug sitting in a pharmacy does nothing for someone who does not know the drug exists, cannot afford it, or cannot reach a clinic that offers it.
The programs also work at the policy level. Medicare’s coverage of lecanemab comes with a requirement that healthcare providers participate in a prospective comparative study, creating a research and oversight framework rather than unlimited access. This approach balances innovation with safety monitoring but also creates administrative burdens for participating sites. In Canada, Health Canada approved lecanemab in October 2025 for people with mild cognitive impairment or early-stage Alzheimer’s disease who have confirmed amyloid pathology. However, coverage timelines differ dramatically between systems: private drug plans in Canada are taking over 1 year to provide access, while public plans are taking over 2 years, illustrating how “approval” and “access” operate on different timelines depending on the funding mechanism.
The Challenge of Getting Approved Drugs to Patients
The infrastructure requirements for delivering current Alzheimer’s therapies create a major accessibility bottleneck. Lecanemab requires intravenous infusions every 2 to 4 weeks, meaning patients must visit an infusion center roughly 12 to 24 times per year. Each visit requires scheduling, transportation, time away from work or family, and often the presence of a caregiver. Many rural areas lack infusion centers altogether, forcing patients to travel 50 to 100 miles for treatment. Additionally, patients must undergo regular MRI scans to monitor for amyloid-related imaging abnormalities, adding further costs and scheduling complexity to the treatment pathway. A patient in a large metropolitan area with access to specialized neurology clinics may find lecanemab relatively accessible; a patient in a small town or an area with limited healthcare infrastructure faces a completely different reality.
The requirement for amyloid biomarker confirmation creates another layer of gatekeeping. Patients cannot receive lecanemab without proof that amyloid accumulation is occurring in their brain, confirmed through either amyloid PET imaging or cerebrospinal fluid (CSF) testing. Amyloid PET scans are expensive, not widely available, and often not covered by insurance unless a patient already has a diagnosis. CSF testing requires a lumbar puncture, an invasive procedure that many patients find uncomfortable or risky. This means that even patients who want to try lecanemab and have access to an infusion center may be unable to begin treatment because they cannot access the diagnostic infrastructure required to confirm amyloid pathology. Accessibility programs attempt to work around this bottleneck by helping patients locate diagnostic centers and navigate insurance approval for these tests, but the underlying limitation remains.
How New Drug Formulations Are Improving Access
Recognizing that IV infusions represent a major barrier, pharmaceutical companies and researchers have invested heavily in developing alternative delivery methods. The August 2025 FDA approval of LEQEMBI IQLIK represents a fundamental shift. This subcutaneous injection can be administered once weekly and critically, patients can give themselves the injection at home. A patient no longer needs to arrange monthly or biweekly trips to an infusion center; they can receive treatment during their regular routine. For someone managing multiple health conditions, balancing work and caregiving responsibilities, or living far from specialized clinics, the ability to treat Alzheimer’s at home rather than in a medical facility is transformative.
The pipeline includes even more simplified formulations. Researchers are developing pill-based therapies for Alzheimer’s disease, though these remain in clinical development. If successful, oral medications would further reduce the burden on patients and healthcare systems. The sheer scale of drug development underway suggests genuine innovation in treatment delivery: 138 drugs are currently being assessed in 182 clinical trials across the Alzheimer’s disease pipeline. However, accessibility improvements in drug formulation cannot fully compensate for gaps in other areas. A patient living in a region with no neurology specialists, unable to afford a biomarker test, and without adequate home support for self-injection would still face barriers despite the drug being easier to administer than IV lecanemab.
Insurance Coverage and Practical Access to Lecanemab
Insurance coverage represents the foundation of accessibility for most patients, yet the coverage landscape remains fragmented. Medicare covers lecanemab, but only for patients whose healthcare providers participate in a prospective comparative study, creating a two-tier system where some beneficiaries have access and others do not depending on their location and which healthcare system they use. Commercial insurance varies by plan, employer, and region. Patients often discover that their insurance covers the drug itself but not the diagnostic testing needed to confirm amyloid pathology, or covers treatment but requires prior authorization processes that delay care by weeks.
The Alzheimer’s Association and other patient advocacy organizations have responded by creating financial assistance programs and patient navigator services that help people understand coverage options and appeal denials. These services address the reality that insurance coverage is not automatic or universal. A 72-year-old patient with Medicare might qualify for coverage but need help understanding the study requirement and finding a participating site. A 65-year-old with commercial insurance through an employer might discover that their plan covers lecanemab but with a $5,000 annual deductible, making the drug unaffordable despite being covered. Accessibility programs attempt to bridge these gaps, but they also highlight the fundamental problem: approval and coverage are not the same, coverage is not the same as affordability, and affordability is not the same as access to the infrastructure required to receive treatment.
The Biomarker Testing Barrier and Its Impact
The requirement for amyloid biomarker confirmation serves an important medical purpose—ensuring that patients likely to benefit from lecanemab receive it—but it creates a significant access barrier. Not all primary care doctors order amyloid testing as part of routine cognitive decline evaluation. Many patients with early symptoms never receive a formal diagnosis or biomarker testing because they never see a neurologist. In some regions, amyloid PET imaging is available at only one or two centers serving populations of hundreds of thousands. Patients seeking biomarker testing may wait months for an appointment.
Even after testing, insurance coverage for amyloid PET imaging varies widely; some plans require it only after a formal Alzheimer’s diagnosis, creating a catch-22 where patients cannot get the diagnosis without testing and cannot get testing covered without a diagnosis. Accessibility programs are working to expand access to biomarker testing through partnerships with diagnostic imaging centers, advocacy for insurance coverage policy changes, and education campaigns encouraging primary care providers to refer patients for evaluation. However, the systemic constraints remain. Lumbar puncture for CSF testing, while less expensive than amyloid PET, carries inherent risks including infection, bleeding, and nerve injury, making it less appealing as a screening tool for early cognitive decline. In summary, even as drug formulations become more accessible, the diagnostic infrastructure determining who qualifies for treatment remains a critical bottleneck.
Support Services and Patient Navigation
The Alzheimer’s Association’s 24-hour Call Center exemplifies the type of support infrastructure that accessibility programs provide. When someone calls 1-800-272-3900, they can speak with staff trained to discuss treatment options, help them understand whether lecanemab might be appropriate, provide information about local dementia specialists, and connect them with support groups and caregiver resources. The Call Center operates across 56 states and territories, providing a consistent resource regardless of geography. For someone newly diagnosed or confused about treatment options, this service can be the difference between pursuing evidence-based care and managing symptoms with only supportive care.
Beyond the national Call Center, accessibility programs operate at the local level through Alzheimer’s Association chapters, hospital-based dementia care programs, and community health centers. These local programs help patients navigate the practical logistics of treatment—arranging transportation to infusion centers, explaining insurance coverage, coordinating care between multiple specialists, and supporting caregivers managing the stress of an Alzheimer’s diagnosis. Some programs provide funds to help patients cover travel costs or copayments. Others offer training on how to self-administer subcutaneous lecanemab injections, reducing anxiety about the medical procedure. These services recognize that accessibility extends beyond whether a drug is approved or covered; it includes the practical, emotional, and logistical support that enables people to actually receive and continue treatment.
The Future of Alzheimer’s Treatment Access
The expansion of the drug pipeline and the development of simpler drug formulations suggest that accessibility will improve significantly over the next five to ten years. As more Alzheimer’s treatments move through clinical trials and toward FDA approval, patients will have options beyond lecanemab, potentially including drugs with different mechanisms of action, different side effect profiles, and different administration requirements. Pill-based therapies, if successful, will eliminate the need for infusions and injections entirely, making treatment accessible to patients who cannot tolerate invasive procedures or reach infusion centers.
The growing recognition of accessibility as a core challenge means that pharmaceutical companies, regulatory agencies, and healthcare systems are designing new drugs and delivery systems with accessibility in mind. However, infrastructure gaps will persist unless matched by investment in healthcare delivery. Expanding access to amyloid biomarker testing, training more neurologists and dementia specialists, supporting primary care providers in recognizing early cognitive decline, and ensuring that insurance coverage keeps pace with medical innovation will all require sustained effort and resources. The transformation of lecanemab from an IV infusion to a home-based subcutaneous injection demonstrates what is possible, but it also highlights that technology and formulation advances, while essential, are only one component of true accessibility.
Conclusion
Treatment accessibility programs work at multiple levels—policy, clinical, and community—to bridge the gap between drug approval and actual patient access. The recent FDA approvals of lecanemab formulations, especially the once-weekly subcutaneous injection approved in August 2025, represent tangible progress. So do the coverage policies and patient support services provided by Medicare, insurance companies, and organizations like the Alzheimer’s Association.
Yet significant barriers remain: the need for specialized diagnostic testing to confirm amyloid pathology, the infrastructure requirements for treatment delivery, the geographic variation in healthcare resources, and the ongoing gaps between insurance coverage and affordability. For someone facing a diagnosis of mild cognitive impairment or early-stage Alzheimer’s disease, the question “Can I access this treatment?” requires navigating multiple systems simultaneously. Starting with a call to the Alzheimer’s Association at 1-800-272-3900 to understand treatment options and local resources is often the first practical step. As the treatment pipeline expands and drug formulations continue to improve, accessibility programs will become increasingly important in ensuring that new advances in Alzheimer’s care reach the people who need them most.
You Might Also Like
- Bench-to-Bedside Programs Accelerate Alzheimer’s Treatment Translation
- Outcome Measurement Tools Standardize Alzheimer’s Treatment Assessment
- Investor Conferences Feature Alzheimer’s Treatment Company Presentations
For more, see Alzheimer’s Association.
